Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Using MRI-Based Remission Criteria: A Prospective, Single-Arm, Multicenter Study

NCT07872449 is registered in ClinicalTrials.gov with Yuki Horio as lead sponsor.

NCT NCT07872449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07872449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Using MRI-Based Remission Criteria: A Prospective, Single-Arm, Multicenter Study
Lead sponsor
Yuki Horio
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
March 31, 2029
Enrollment
25 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, perianal crohn's disease, perianal fistula, perianal fistula due to crohn's disease